https://www.businesswire.com/news/home/20250403023818/en/Sangamo-Therapeutics-Announces-Capsid-License-Agreement-With-Lilly-to-Deliver-Genomic-Medicines-for-Diseases-of-the-Central-Nervous-System
SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
sangamo therapeuticslicense agreementannouncescapsidlilly
https://www.sangamo.com/
Feb 28, 2026 - Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene...
sangamo therapeuticsincpioneeringgeneticcures